-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Innoviva, Lowers Price Target to $34

Benzinga·11/05/2026 17:44:54
Listen to the news
Oppenheimer analyst Les Sulewski maintains Innoviva (NASDAQ:INVA) with a Outperform and lowers the price target from $35 to $34.